Treatment of human T-cell acute lymphoblastic leukemia cells with CFTR inhibitor CFTRinh-172

Leuk Res. 2019 Nov:86:106225. doi: 10.1016/j.leukres.2019.106225. Epub 2019 Sep 13.

Abstract

Our previous studies have demonstrated that a previously unrecognized role of CFTR in hematopoiesis and acute leukemia. Here, we show that CFTR inhibitor CFTR-inh172 possesses ability to inhibit human T-cell acute lymphoblastic leukemia cells. In detail, CFTR-inh172 inhibited cell proliferation, promoted apoptosis and arrested the cell cycle in human T-cell acute lymphoblastic leukemia cell CCRF-CEM, JURKAT and MOLT-4. Furthermore, transcriptome analysis reveals that CFTR-inh172 induces significant alteration of gene expression related to apoptosis and proliferation. These findings demonstrate the potential of CFTR inhibitor CFTR-inh172 in human T-cell acute lymphoblastic leukemia treatment.

Keywords: CFTR; CFTRinh-172; Human T-cell acute lymphoblastic leukemia; Treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • Benzoates / pharmacology*
  • Cell Cycle / drug effects*
  • Cell Proliferation / drug effects*
  • Cystic Fibrosis Transmembrane Conductance Regulator / antagonists & inhibitors*
  • Gene Expression Regulation / drug effects*
  • Humans
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
  • Signal Transduction
  • Thiazolidines / pharmacology*
  • Transcriptome
  • Tumor Cells, Cultured

Substances

  • 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone
  • Benzoates
  • CFTR protein, human
  • Thiazolidines
  • Cystic Fibrosis Transmembrane Conductance Regulator